CJC-1295 + Ipamorelin

CJC-1295 with DAC: Sackmann-Sala et al. (2006, JCEM, PMID 16352683) — dose-dependent GH elevation 2-10x baseline sustained for 6 days, IGF-1 elevation 1.5-3x sustained for 9-11 days after a single injection in healthy human adults. Multiple injections produced IGF-1 elevation sustained for up to 28 days. This is the most robustly human-validated effect in the chapter. Ipamorelin: GH pulse confirmed in pharmacological characterization studies with the GH peak at 40-60 minutes post-injection. No large-scale human biomarker RCT comparable to the CJC-1295 DAC trial. The specific CJC-1295 no-DAC + Ipamorelin combination: biomarker outcome confirmed in mechanistic literature via the GHRH + GHRP synergy principle; no formal Phase 2/3 GH measurement study for this exact combination published.

The body composition evidence for GH secretagogues is extrapolated from the broader GH/IGF-1 literature. GH directly stimulates lipolysis — mobilizing fatty acids from adipose tissue for energy — and IGF-1 promotes protein synthesis and muscle preservation. The somatopause (age-related GH decline beginning in the third decade) is associated with increasing fat mass, particularly visceral fat, and decreasing lean mass. GH replacement in adults with documented GH deficiency produces measurable improvements in body composition. Whether GH secretagogue-driven GH elevation in non-GH-deficient individuals produces equivalent benefits is not directly established in controlled body composition trials for CJC-1295/Ipamorelin. The evidence that does exist: older GHRH and GHRP studies showing body composition improvements, community consensus across years of clinical use, and mechanistic logic. Grade B-C: indirect evidence through related compounds and mechanisms; no dedicated body composition RCT for CJC-1295/Ipa.

GH is predominantly released during slow-wave (deep) sleep, with the largest pulse occurring 1-2 hours after sleep onset. GH secretagogue administration before sleep amplifies this natural sleep-associated GH pulse. The deeper GH pulse during slow-wave sleep may reinforce sleep depth and continuity — consistent with the GH system's normal bidirectional interaction with sleep architecture. Community users consistently report improved sleep quality as the first perceptible benefit of CJC-1295/Ipamorelin protocols, typically within 1-2 weeks of starting nightly bedtime administration. Grade B-C: mechanistically sound; consistent with GH physiology; community consensus strong; no controlled sleep study specifically for this combination.

GH and IGF-1 support connective tissue synthesis, bone remodeling, and muscle protein synthesis — the fundamental biological infrastructure of tissue repair. CJC-1295/Ipamorelin does not have the direct healing peptide mechanisms of BPC-157 or TB-500 (no VEGF angiogenesis, no actin migration, no gut-specific healing). Its contribution to recovery is systemic anabolic support via the GH axis: enhanced protein synthesis, improved nitrogen retention, and accelerated regeneration through IGF-1-mediated signaling. Grade C (indirect evidence through GH replacement literature; plausible for recovery; not tested in injury models).

GH has complex metabolic effects: it promotes lipolysis (fat breakdown), but high GH levels also produce insulin resistance by impairing insulin-mediated glucose uptake in muscle. The sustained GH elevation from CJC-1295 DAC is more associated with insulin sensitivity concerns than the pulsatile pattern from CJC-1295 no-DAC + Ipamorelin. IGF-1 itself improves insulin sensitivity (counterbalancing some of GH's insulin-antagonizing effects). The net metabolic effect at community doses is generally fat loss with muscle preservation, but users with pre-existing insulin resistance or metabolic syndrome should monitor fasting glucose. Grade C-D (GH/IGF-1 metabolic effects established; CJC/Ipa specific metabolic data absent).

The GH/IGF-1 axis is bidirectionally linked to aging: GH declines progressively from peak in early adulthood, and lower GH/IGF-1 is associated with features of aging. Restoration of more youthful GH levels through secretagogues is a central rationale in anti-aging medicine. However, the IGF-1 pathway is also associated with cancer risk and accelerated aging in some models (the 'IGF-1 paradox' — long-lived organisms like centenarians often have lower IGF-1). Whether restoring youthful GH/IGF-1 levels extends healthy longevity or potentially accelerates certain aging processes through chronic IGF-1 elevation is not settled. Grade D (compelling rationale; contested long-term evidence; no longevity trial for this combination).

CJC-1295 is a 29-30 amino acid synthetic peptide based on the first 29 amino acids of human GHRH (GHRH 1-29, also known as Growth Hormone Releasing Factor 1-29 or GRF 1-29). Four amino acid substitutions compared to native GHRH provide resistance to DPP-IV degradation: D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27. These substitutions make CJC-1295 approximately 4x more potent and substantially more stable than native GHRH 1-29. The base peptide without the DAC modification has a half-life of approximately 30 minutes — versus endogenous GHRH's 7 minutes.

NAMING CONFUSION — READ BEFORE ORDERING OR DOSING

The terms 'CJC-1295,' 'Modified GRF 1-29,' 'Mod GRF,' and 'CJC-1295 without DAC' are used interchangeably by different vendors, clinicians, and community members to describe the SAME short-acting compound. 'CJC-1295 with DAC' or 'CJC-1295 DAC' refers to the DIFFERENT long-acting albumin-binding form. A COA mass spectrometry read: ~3,368 Da = CJC-1295 without DAC (Modified GRF 1-29). ~3,760 Da = CJC-1295 with DAC (includes the maleimidopropionyl modification). Before any purchase or protocol, confirm which form you have by mass spectrometry.

Form

Other Names

MW

Half-Life

Clinical Use

CJC-1295 without DAC

Modified GRF 1-29; Mod GRF; GRF(1-29)

~3,368 Da

~30 minutes

Gold standard for pulsatile + Ipamorelin stack. Daily dosing required. Preferred for physiological pulsatility.

CJC-1295 with DAC

CJC-1295 DAC; DAC:GRF

~3,760 Da

~6-8 days

Sustained GH elevation. Weekly dosing. Convenient but eliminates pulsatile synergy with Ipamorelin.

Ipamorelin is a synthetic pentapeptide (5 amino acids): Aib-His-D-2-Nal-D-Phe-Lys-NH₂. Molecular weight approximately 711 Da. CAS: 170851-70-4. The two D-amino acid residues and the C-terminal amide provide metabolic stability. Half-life approximately 1.5-2.5 hours after SubQ injection; GH peak typically at 40-60 minutes post-injection. Unlike the GHRPs of the previous generation (GHRP-6 at 873 Da, GHRP-2 at 818 Da), ipamorelin's specific structure confers its defining property: GHS-R1a selectivity that produces clean GH release without ACTH/cortisol activation.

Both compounds: lyophilized powder stable 18-24 months at -20C. Reconstituted with bacteriostatic water, refrigerate at 2-8C, use within 30 days. Solutions are clear and colorless. Mass spectrometry is the only identity confirmation. For CJC-1295 without DAC: ~3,368 Da. For Ipamorelin: ~711 Da. Often purchased as a pre-mixed blend in a single vial — verify mass spec for both compounds if purchasing a blend.

CJC-1295 binds to GHRH receptors on pituitary somatotroph cells with high affinity and activates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP) levels. This cAMP elevation activates protein kinase A (PKA), which phosphorylates transcription factors including CREB and CRE-binding proteins, upregulating GH gene expression and triggering GH secretion. The four amino acid substitutions in CJC-1295 resist DPP-IV cleavage — DPP-IV cleaves at the Ala-Glu bond at positions 1-2 in native GHRH, inactivating it. The D-Ala at position 2 blocks this cleavage. The result is a peptide that activates the GHRH receptor with essentially the same pharmacological profile as native GHRH but with dramatically extended plasma half-life.

CJC-1295 without DAC: the base peptide activates GHRH receptors for ~30 minutes, producing a GH pulse that mirrors physiological GHRH signaling in its timing and peak profile but with greater amplitude. The receptor returns to baseline between doses, maintaining physiological pulsatility. CJC-1295 with DAC: the albumin-conjugated form continuously occupies GHRH receptors. Ionescu & Frohman (2006 [2], PMID 17018654) showed that pulsatile GH secretion persists even during continuous CJC-1295 stimulation — basal GH levels increase 7.5-fold, pulses continue to occur, and IGF-1 remains elevated. Whether this 'GH bleed' pattern produces equivalent physiological benefits to the classic pulsatile pattern — or whether the chronically elevated baseline reduces receptor sensitivity over time — is not conclusively answered.

Ipamorelin binds to the ghrelin receptor (GHS-R1a) on pituitary somatotrophs and hypothalamic neurons. GHS-R1a activation couples to Gαq/Gαs proteins, elevating intracellular calcium through PLC-IP3 signaling — a completely different intracellular cascade than the cAMP mechanism of CJC-1295. This calcium-mediated signaling triggers a rapid, sharp GH pulse distinct in character from the smoother, more sustained CJC-1295-driven release.

The selectivity of ipamorelin for this receptor is its defining pharmacological property. GHRP-6 and GHRP-2 also activate GHS-R1a but have secondary actions on ACTH/cortisol pathways. Ipamorelin's structure provides specific binding geometry that engages the GH-releasing function of GHS-R1a without triggering the ACTH cascade. Raun et al. (1998) confirmed that even at 200x the GH-releasing ED50 — doses far above any clinical use — ipamorelin produced no significant ACTH or cortisol elevation. This makes ipamorelin the clean tool for GH optimization without the HPA axis activation that complicated earlier GHRPs.

The synergy between CJC-1295 (no DAC) and Ipamorelin operates at two levels. First, dual receptor activation: GHRH receptor stimulation (cAMP/PKA pathway) and GHS-R1a stimulation (calcium/PLC pathway) simultaneously activate two independent intracellular GH secretion cascades. The combined effect exceeds what either pathway produces alone — documented as 5-10x baseline GH in studies of GHRH + GHRP combinations. Second, the hypothalamic amplification: GHS-R1a stimulation by Ipamorelin also triggers GHRH release from the hypothalamus, providing an additional GHRH signal on top of the exogenous CJC-1295 already present.

The specific CJC-1295 without DAC + Ipamorelin combination has not been studied in a controlled human trial directly — the synergy evidence comes from older GHRH + GHRP-6 studies. The mechanistic extrapolation to CJC-1295/Ipa is pharmacologically sound: same receptor pathways, same signaling mechanisms, same independence between the two cascades. The ipamorelin substitution is supported by its superior selectivity profile. Grade B for the specific combination: strong mechanistic basis + indirect evidence from GHRH/GHRP family; no direct CJC-1295/Ipa combination RCT.

Recombinant human GH (rhGH) bypasses the pituitary entirely, delivering exogenous GH directly into circulation. This produces continuous, non-pulsatile GH elevation that suppresses endogenous GH release via negative feedback (elevated IGF-1 suppresses GHRH and stimulates somatostatin), accelerates pituitary GH cell desensitization, and maintains IGF-1 continuously above physiological pulsatile-release levels. The GH secretagogue approach preserves the pituitary axis — the pituitary continues producing GH naturally, with secretagogues amplifying rather than replacing its activity. Negative feedback remains operative. Pulsatility is maintained. The pituitary axis does not shut down. This is the fundamental pharmacological argument for secretagogues over exogenous rhGH, and why GH secretagogues became the preferred approach in functional and anti-aging medicine before the 2023 FDA restrictions.

GH SECRETAGOGUE VS EXOGENOUS HGH — THE KEY DISTINCTION

GH secretagogues (CJC-1295 + Ipamorelin): stimulate the pituitary to produce more of its own GH. Pulsatility preserved. Negative feedback intact. IGF-1 rises within the physiological range for age. Pituitary does not shut down. Exogenous recombinant HGH: delivers GH directly. Pituitary GH production suppressed. IGF-1 driven above normal ranges at typical doses. Pulsatility eliminated. More side effects. Much higher cost. The secretagogue approach is the reason this chapter exists as a standalone stack rather than a minor footnote to an HGH chapter. They are mechanistically different therapeutic strategies.

Parameter

CJC-1295 Without DAC (Mod GRF)

CJC-1295 With DAC

Ipamorelin

Half-life

~30 minutes

~6-8 days

~1.5-2.5 hours

GH pulse pattern

Sharp pulse; GHRH receptor resets

Sustained elevation; continuous GHRH-R occupancy

Sharp pulse at 40-60 min post-dose

Dosing frequency

Daily (usually 1-2x/day)

Weekly or 2x/week

Daily (1-3x/day)

Synergy with Ipamorelin

YES — classic synergistic pulse; co-inject together

LIMITED — continuous receptor occupancy changes pulse dynamics

Either CJC form, but classic synergy with no-DAC

IGF-1 profile

Pulsatile elevation; returns toward baseline between doses

Sustained 1.5-3x elevation for 9-11 days per injection

Contributes to GH pulse; indirect IGF-1 support

Both compounds: lyophilize powder reconstituted with bacteriostatic water. Clear, colorless solution. Refrigerate at 2-8C; use within 30 days. For pre-mixed blends (CJC-1295 + Ipamorelin combined in one vial): same reconstitution process; volume calculations apply to the combined compound mass.

Vial

BAC Water

Concentration

Notes

CJC-1295 no-DAC, 2 mg

2.0 mL

1,000 mcg/mL

Standard — 100 mcg = 10 units (U-100)

CJC-1295 no-DAC, 5 mg

5.0 mL

1,000 mcg/mL

Larger vial; same working concentration

Ipamorelin 2 mg

2.0 mL

1,000 mcg/mL

Standard — 100 mcg = 10 units

Ipamorelin 5 mg

5.0 mL

1,000 mcg/mL

Larger vial

Pre-mixed 10 mg blend (5mg each)

5.0 mL total

1,000 mcg/mL each (~2,000 total)

100 mcg of each per 10 units (U-100); verify blend ratio on COA

CJC-1295 with DAC, 2 mg

2.0 mL

1,000 mcg/mL

Weekly injection; handle differently from no-DAC

TIMING IS EVERYTHING — THE MOST IMPORTANT DOSING RULE

GH release is powerfully suppressed by elevated blood glucose and insulin. Somatostatin (the GH inhibitor) is released in response to high glucose — completely blunting the GH pulse that CJC-1295 + Ipamorelin tries to produce. The protocol must be administered on an empty stomach, with no carbohydrates or significant calories for at least 2 hours before the injection. Most users administer before bed (last meal 2+ hours prior) to align with the natural sleep-associated GH pulse. Injecting after a meal containing carbohydrates eliminates most of the therapeutic pulse. This is not a minor pharmacokinetic detail — it is the difference between a 5-10x GH pulse and a 1-2x blunted response.

Phase

CJC-1295 No-DAC

Ipamorelin

Timing

Duration

Introduction

100 mcg

100 mcg

Once daily, bedtime (empty stomach)

Weeks 1-2; assess tolerance

Standard maintenance

100-200 mcg

100-200 mcg

Once daily, bedtime OR twice daily (AM + PM)

Weeks 3 onwards; most common clinical protocol

Advanced

200-300 mcg

200-300 mcg

Twice daily maximum

Experienced users; diminishing returns above 300 mcg per dose per compound

Twice-daily protocol

100-200 mcg

100-200 mcg

Both AM (fasted) + bedtime

For body composition emphasis; requires strict carbohydrate timing

CJC-1295 with DAC is appropriate when: (1) dosing convenience is the primary concern — once-weekly or twice-weekly injection is more adherent for some patients than daily; (2) the goal is sustained IGF-1 elevation for anti-aging or body composition rather than the specific synergistic pulse; (3) the patient cannot reliably maintain the empty-stomach timing requirement for no-DAC. Protocol: CJC-1295 DAC 1-2 mg once weekly. Ipamorelin can be co-administered or run on its own daily schedule — but note that the synergistic pulse dynamic is reduced with the DAC form. Some practitioners combine weekly CJC-1295 DAC with daily bedtime Ipamorelin as a hybrid: DAC provides sustained GH baseline; Ipamorelin adds daily pulsatile enhancement. This is community-derived and not validated in a comparison study.

Standard clinical cycle: 3-6 months continuous, then reassess. Some practitioners use 5-days-on/2-days-off weekly schedules. Some run continuous protocols. Unlike anabolic steroids, GH secretagogues do not suppress the HPTA axis — cessation does not require PCT. The pituitary axis returns to normal baseline after discontinuation. Long-term use beyond 6-12 months: insufficient safety data; theoretical concern about pituitary desensitization at sustained doses. Monitor IGF-1 levels on-cycle as a safety and efficacy marker.

IGF-1 blood level is the primary objective monitoring tool. Pre-protocol baseline IGF-1 establishes starting point. Target: bring IGF-1 into the upper-third of the age-normal reference range — not above the age-adjusted normal range. IGF-1 significantly above the normal range for age is associated with increased cancer risk and acromegalic side effects. Most clinicians target IGF-1 in the 200-300 ng/mL range for adults over 40 — within normal, toward the upper quartile for age, but not supraphysiological. Check at 6-8 weeks into a protocol; adjust dose if IGF-1 is above range. Fasting glucose baseline and on-cycle monitoring for insulin sensitivity changes.

• Water retention and mild edema: the most commonly reported early side effect. IGF-1 elevation promotes sodium and water retention. Typically self-limiting after 2-4 weeks as the body adjusts. More pronounced with the DAC form and its sustained IGF-1 elevation.
• Tingling in extremities (paresthesia): a hallmark GH effect — also seen with exogenous HGH. Particularly in hands and wrists (carpal tunnel-like sensation). Usually transient; resolves with dose reduction or time. More common with DAC form and at higher doses.
• Injection site reactions: mild redness and swelling. Standard SubQ injection reactions; manageable.
• Headache: occasional, typically in the first week as GH begins to rise. Usually transient.
• Transient fatigue: occasionally reported in the first 1-2 weeks. Inconsistent; resolves spontaneously.
• Morning lethargy: bedtime dosing produces GH pulse during sleep — some users report heavier, groggier morning waking in the first 1-2 weeks. Usually resolves; some find morning dosing for the second injection avoids this.

GH has dose-dependent insulin-antagonizing effects — it reduces insulin sensitivity in peripheral tissues. This is more relevant with sustained GH elevation (DAC form) than with the pulsatile no-DAC pattern, where troughs allow insulin sensitivity to recover between peaks. At typical community doses of CJC-1295 no-DAC + Ipamorelin, clinically significant insulin resistance is uncommon in metabolically healthy individuals. However: diabetics, pre-diabetics, and metabolically compromised users should monitor fasting glucose carefully. The combination of CJC/Ipa with GLP-1 agonists (semaglutide, tirzepatide) — popular in the anti-aging community — requires physician oversight to avoid glucose management complications.

ACTIVE MALIGNANCY — ABSOLUTE CONTRAINDICATION

GH and IGF-1 are growth factors that promote cellular proliferation through the IGF-1R/mTOR pathway — the same pathway that drives tumor growth in many cancers. Elevating GH and IGF-1 through CJC-1295/Ipamorelin in a patient with active malignancy could potentially accelerate tumor growth or metastasis. This contraindication applies to any active cancer and recent cancer (within 2-5 years depending on cancer type). For any user with a personal cancer history: discuss with oncologist before initiating any GH secretagogue protocol. This is a mechanistically grounded hard stop, not a theoretical caution.

• Pregnancy and breastfeeding: no safety data; GH axis involvement warrants avoidance.
• Active acromegaly or pituitary disease: direct contraindication — these conditions involve pathological GH excess.
• Diabetic retinopathy: GH can worsen retinal microangiopathy; contraindicated.
• Pediatric use: GH physiology in growth-stage children requires specialized care; not for non-physician use in pediatric patients.

Unlike anabolic steroids, SARMs, or exogenous HGH, GH secretagogues do not suppress the hypothalamic-pituitary-testicular axis (HPTA). They stimulate the somatotropic axis (GH/IGF-1), not the gonadal axis. Testosterone production is unaffected. No post-cycle therapy is required or indicated. This is a significant safety advantage in the context of performance and anti-aging peptide use.

The regulatory status of CJC-1295 and Ipamorelin in 2026 is more complex than the peptides reviewed in prior chapters, and the two compounds differ from each other:

• CJC-1295 — Developmental Drug Classification: CJC-1295 (both with and without DAC) was developed by ConjuChem Biotechnologies as a clinical drug candidate. Because it has been the subject of formal Investigational New Drug (IND) applications and clinical trials, the FDA classifies it as a 'developmental drug' — meaning it falls under different restrictions than simple research chemicals. In 2026, CJC-1295 is in a stricter regulatory category than the PCAC-reviewed compounds (BPC-157, TB-500, KPV, MOTS-c, Semax). The nomination for compounding was withdrawn from Category 2 in 2026, but CJC-1295 faces ongoing FDA scrutiny as a developmental drug. Physicians who prescribe it through compounding pharmacies operate in a legally complex space that has been subject to FDA enforcement actions. Users should understand this distinction — CJC-1295 is not in the same regulatory category as the PCAC-review compounds being reconsidered for open compounding.
• Ipamorelin — Category 1 Status: Ipamorelin maintains Category 1 status in the FDA 503A bulk drug substances list — meaning it is permitted for compounding pharmacies to produce for prescription use. This is a more favorable regulatory status than CJC-1295 and the Category 2 compounds. Physician-prescribed Ipamorelin through licensed compounding pharmacies is the most legally defensible access pathway in the US as of 2026.

WADA STATUS — BOTH COMPOUNDS EXPLICITLY BANNED

Both CJC-1295 and Ipamorelin are explicitly banned under the 2026 WADA Prohibited List, Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). S2.2 covers 'Growth hormone secretagogues, e.g. ipamorelin, lenomorelin.' S2.1 covers GH-releasing factors including GHRH analogs. The bans are at all times (in and out of competition). No TUE available. This covers all competitive athletes in all WADA-signatory sports and organizations. Military personnel subject to USADA rules, NCAA athletes, and any tested professional or competitive athlete must treat both compounds as categorically prohibited.

The combination chapter IS the stack. The entire purpose of pairing these compounds is synergistic dual-pathway GH release — CJC-1295 (GHRH-R pathway, cAMP) + Ipamorelin (GHS-R1a pathway, calcium). Running either alone produces a fraction of the GH response of the combination. The key operational points: co-inject in the same syringe or separate syringes within the same injection session (timing matters for the synergistic pulse); maintain empty-stomach protocol; dose before sleep for the natural GH pulse amplification; monitor IGF-1 as the objective efficacy and safety marker.

For users running GLOW or KLOW healing peptide protocols who want to add GH secretagogue support, the CJC/Ipa + GLOW combination addresses complementary axes: GLOW targets ECM quality, collagen synthesis, angiogenesis, and anti-inflammatory NF-κB suppression; CJC/Ipa provides the systemic anabolic GH pulse that supports the protein synthesis and tissue remodeling that GLOW's mechanisms drive. No pharmacological conflicts exist between these compounds. The combination requires dose management and timing: GLOW typically daily SubQ; CJC/Ipa bedtime, on an empty stomach.

Adding MOTS-c to a GH secretagogue protocol creates a layered metabolic approach: CJC/Ipa drives GH/IGF-1 anabolic signaling; MOTS-c activates AMPK-driven metabolic efficiency and mitochondrial biogenesis. These are complementary rather than redundant (GH axis anabolism vs AMPK-driven catabolism-metabolic efficiency). The AMPK/mTOR tension noted in the MOTS-c chapter (AMPK suppresses mTOR anabolic signaling) applies here: combining an anabolic GH pulse protocol with a catabolic/metabolic MOTS-c protocol creates a push-pull dynamic. Some practitioners believe this combination produces better body recomposition than either alone. No data. Athletes: both WADA banned.

For recovery-focused users, CJC/Ipa provides the systemic GH/IGF-1 anabolic environment that maximizes the structural repair work done by BPC-157, TB-500, and GHK-Cu. The healing peptides repair tissue architecture; the GH secretagogues provide the anabolic signaling environment that facilitates protein deposition in those repaired structures. Many clinical practitioners use this combination for post-surgical recovery, age-related musculoskeletal decline, and athletic recovery optimization. No direct combination efficacy trial. Mechanistic rationale is sound.

Sermorelin is an FDA-approved GHRH analog (approved for pediatric GH deficiency but used off-label in adults) with a shorter half-life than even CJC-1295 no-DAC (~10-12 minutes) and less potency. Sermorelin is the most regulatory-safe GH secretagogue option but requires more frequent dosing and produces smaller GH pulses. CJC-1295 no-DAC + Ipamorelin produces significantly larger GH responses. The choice between them often comes down to regulatory risk tolerance and clinical goal: Sermorelin for conservative, physician-supervised anti-aging; CJC-1295/Ipa for more aggressive GH optimization.

Timeframe

What You May Notice

Week 1-2

Improved sleep depth is typically the first reported effect — deeper, more restorative sleep within days of starting bedtime administration. Some users report more vivid dreams. Mild transient fatigue or grogginess upon waking in the first week.

Week 2-4

Reduced water retention (initial bloating from IGF-1 rise often self-resolves). Early improvements in energy and recovery from exercise. Tingling in hands/feet may appear in this window if dose is too high — reduce dose if persistent.

Week 4-8

Body composition changes becoming perceptible: reduced fat (particularly visceral), improved muscle firmness and recovery. Most community users report this as the most noticeable phase.

Week 8-12

More significant body composition changes for users with consistent nutrition and exercise. IGF-1 check at week 6-8 — adjust dose based on result.

Month 3-6

Full protocol benefit realized. Some practitioners see additional improvement with dose adjustment based on IGF-1 monitoring. Anti-aging effects (skin quality, energy, recovery) most consistently reported in this window.

• Empty stomach for every injection: the single most impactful compliance factor. No carbohydrates for 2+ hours before injection. Somatostatin blunting from postprandial insulin elevation eliminates most of the pulse.
• Bedtime timing alignment: natural GH pulse during slow-wave sleep (1-2 hours post sleep onset) is amplified by bedtime CJC/Ipa injection. This timing alignment produces the largest combined physiological + pharmacological pulse.
• IGF-1 monitoring: dose adjustments based on actual IGF-1 levels rather than guessing. Target upper-third of age-normal range, not supraphysiological.
• Consistent nutrition with adequate protein: the GH pulse triggers protein synthesis, but that synthesis requires adequate amino acid substrate. High-protein diet amplifies the anabolic response.
• Resistance training: GH and IGF-1 effects on muscle require the anabolic stimulus of resistance exercise. Without training, the body composition response is significantly attenuated.
• Avoid exogenous HGH simultaneously: stacking exogenous rhGH with GH secretagogues suppresses the somatotropic axis the secretagogues are designed to amplify. Redundant and potentially counterproductive.

• Injecting after eating: the most common protocol failure. Carbohydrate-induced insulin response triggers somatostatin release, blocking the GH pulse. Two hours minimum fasting before each injection.
• Using CJC-1295 with DAC and expecting the gold-standard synergistic pulse: the synergistic pulse requires both receptor pathways to be activated simultaneously from a resting state. With DAC continuously occupying the GHRH receptor, the classic synergy is diminished. If synergistic pulsatility is the goal, use without-DAC.
• Confusing compound names (CJC-1295 vs Mod GRF 1-29): they are the same compound. Confirm by molecular weight on the COA. The vendor's chosen name is irrelevant; the mass spec result is the identity proof.
• Not monitoring IGF-1: IGF-1 supraphysiological elevation is the primary safety risk. Running GH secretagogues without IGF-1 monitoring is operating blind on the most important safety and efficacy marker.
• Expecting HGH-equivalent results at typical doses: GH secretagogues produce more physiological GH levels than exogenous HGH. The results are typically subtler in the short term — more sustainable but less dramatic than the supraphysiological effects of high-dose rhGH.

GH secretagogues do not suppress the HPTA axis. No PCT required. The pituitary somatotropic axis returns to its pre-protocol baseline within days to weeks of stopping. The body composition changes achieved during the protocol persist according to normal physiology — muscle maintained with continued training, fat does not immediately rebound. Standard cycles of 3-6 months on, with 1-2 month breaks, are common clinical practice. Some practitioners use continuous protocols with quarterly IGF-1 monitoring. No published data on optimal cycling vs continuous use.

Two access pathways in 2026: (1) Physician-supervised compounding pharmacy prescription — the legally compliant route for Ipamorelin (Category 1). CJC-1295 through compounding pharmacies is in a more legally complex space (developmental drug classification); discuss with prescribing physician. (2) Research chemical vendors — same quality concerns as other peptides in this book.

COA requirements: CJC-1295 without DAC: HPLC purity 98%+ and mass spec confirming ~3,368 Da. CJC-1295 with DAC: HPLC purity 98%+ and mass spec confirming ~3,760 Da. Ipamorelin: HPLC purity 99%+ (smaller peptide, truncated sequences more consequential) and mass spec confirming ~711 Da. Endotoxin below 0.1 EU/mg for injectable use. Pricing 2026: research vendor with full COA — CJC-1295 no-DAC 5 mg: $35-60; Ipamorelin 5 mg: $30-50; pre-mixed blends 10 mg (5mg each): $50-80.

CJC-1295 + Ipamorelin was the dominant GH secretagogue protocol in US compounding pharmacy practice before the 2023 FDA restrictions. The protocol was used by tens of thousands of patients under physician supervision — an unusually large clinical experience base for a peptide that lacks formal Phase 3 efficacy trials. The community consensus from this experience is consistent: sleep improvement within the first 2 weeks is the most reliable early benefit; body composition changes develop over months; recovery improvements are meaningful for active individuals; the protocol is better tolerated than exogenous HGH with fewer side effects at comparable GH axis support.

The most important practical distinction from the clinical experience: the patients who saw the best results combined consistent resistance training with protein-rich nutrition and strict empty-stomach timing. Users who treated it as a passive supplement without optimizing the other inputs saw modest or no results. The GH pulse is a signal to the body to build and repair — it requires the substrate and stimulus to produce structural changes.

Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. (2006). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research. 16(5-6):379-391. PMID: 16352683. [THE primary CJC-1295 human clinical study — Phase 2, dose-dependent GH 2-10x, IGF-1 1.5-3x; single injection efficacy for 6-11 days]

Ionescu M, Frohman LA. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 91(12):4792-7. PMID: 17018654. [Human PD study — basal GH 7.5x; pulsatility preserved during continuous CJC-1295 DAC stimulation]

Teichman SL, Neale A, Lawrence B, et al. (2006) [3]. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 91(3):799-805. PMID: 16352683. [Multiple-dose human trial; IGF-1 elevated up to 28 days with repeated injections]

Raun K, Hansen BS, Johansen NL, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 139(5):552-61. PMID: 9849822. [THE foundational paper — ipamorelin as first selective GHS; no ACTH/cortisol elevation at 200x ED50; swine model confirmed; basis for clinical selectivity framing]

Bowers CY, Sartor AO, Reynolds GA, Badger TM. (1991) [5]. On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology. 128(4):2027-35. [Early GHRH + GHRP synergy characterization — dual pathway activation]

Jaffe CA, Ho PJ, Demott-Friberg R, et al. (1993) [6]. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. J Clin Endocrinol Metab. 77(5):1641-7. PMID: 8077347. [Human GHRP/GHRH synergy studies establishing the dual-pathway principle]

Jetté L, Léger R, Thibaudeau K, et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 146(7):3052-8. PMID: 15802494. [CJC-1295 albumin-binding mechanism; in vivo GH elevation up to 14 days in rats]

Bailey RT Jr, Brunner RC. (2007) [8]. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 293(6):E1476-82. [Independent; normalized growth with daily administration in GHRH-deficient mice]

FDA. (2026). CJC-1295 — Developmental Drug Classification; nominated for 503A Category 2 withdrawn April 22, 2026. Ongoing FDA scrutiny under developmental drug framework.

FDA. (2022). Ipamorelin — maintains Category 1 status on 503A Bulks List; permitted for compounding pharmacy prescription production.

WADA. (2026). Prohibited List S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. S2.2: 'Growth hormone secretagogues, e.g. ipamorelin, lenomorelin.' S2.1: GHRH analogs. Both CJC-1295 and Ipamorelin prohibited at all times.

Well-suited for: adults over 40 experiencing somatopause-related decline (reduced muscle mass, increased fat, poor sleep, slow recovery) who want to optimize the GH axis through the body's own pituitary; users who have tried other anti-aging approaches and want to address the hormonal substrate; anyone with a physician willing to supervise IGF-1 monitoring and dose optimization; users already running healing peptide stacks who want to add the systemic anabolic environment that amplifies their repair work.

Extra caution for: anyone with active malignancy or recent cancer history (hard stop — IGF-1 is a growth factor); diabetics and metabolically compromised individuals (monitor glucose carefully); athletes under any anti-doping testing (both compounds WADA S2 banned, no TUE, hard stop).

Not appropriate for: active cancer (absolute contraindication); athletes under WADA testing (both explicitly banned); users expecting exogenous HGH-equivalent dramatic results at typical GH secretagogue doses; users who cannot maintain empty-stomach dosing timing (eliminates most of the pulse).

If your priority is...

Choose

Maximum synergistic GH pulse, pulsatility preservation

No-DAC + Ipamorelin (gold standard)

Dosing convenience (weekly injection)

With-DAC (weekly) + optional daily Ipamorelin

Most physiological GH pattern

No-DAC + Ipamorelin

IGF-1 sustained above age-normal range

With-DAC (sustained IGF-1 elevation for 9-11 days per injection)

Anti-aging / sleep / recovery

No-DAC + Ipamorelin (bedtime) — pulsatility matches natural sleep GH pulse

Research use, single-compound GH elevation without GHRP

Either CJC-1295 form alone (no Ipamorelin needed for biomarker studies)

• 'CJC-1295' without specifying DAC status: the two forms are different compounds with different pharmacokinetics and different clinical applications. Any protocol, paper, or community post that says 'CJC-1295' without specifying DAC/no-DAC is ambiguous and potentially misleading. Always clarify.
• Grade A evidence for GH elevation = Grade A evidence for body composition outcomes: the CJC-1295 human trials measured GH and IGF-1. They did not measure body composition, recovery, sleep, or any clinical outcome. The translation from biomarker to clinical outcome is extrapolated from GH physiology, not demonstrated in controlled trials for this combination.
• No HPTA suppression = no safety concerns: GH secretagogues preserve the HPTA axis. They still elevate IGF-1, which has cancer risk implications, insulin-antagonizing metabolic effects, and requires monitoring. No HPTA suppression does not mean no risks.
• More is better: GH secretagogues have a ceiling on their GH-releasing capacity (the pituitary can only release as much GH as it has available). Above a certain dose, more CJC/Ipa does not produce proportionally more GH. The dose-response relationship flattens. Driving IGF-1 above the upper-normal range through excess dosing produces side effects without proportional benefit.

— End of CJC-1295 + Ipamorelin —

THE PEPTIDE BIBLE | CJC-1295 + Ipamorelin | For Research & Educational Purposes Only